|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCB11 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCC2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
decreases expression multiple interactions increases expression |
ISO |
enilconazole results in decreased expression of ABCC3 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA enilconazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:29451352 PMID:33426623 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCD3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCD3 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 1:94,385,131...94,518,663
Ensembl chr 1:94,418,389...94,518,666
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of ACOX1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177
|
|
G |
ADH1A |
alcohol dehydrogenase 1A (class I), alpha polypeptide |
decreases expression multiple interactions |
EXP |
enilconazole results in decreased expression of ADH1A mRNA [clothianidin co-treated with enilconazole] results in decreased expression of ADH1A mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of ADH1A mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ADH1A mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:99,276,369...99,290,985
Ensembl chr 4:99,276,369...99,291,003
|
|
G |
ADK |
adenosine kinase |
increases expression |
EXP |
enilconazole results in increased expression of ADK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:74,151,221...74,709,290
Ensembl chr10:74,151,202...74,709,963
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
multiple interactions increases expression decreases expression |
EXP ISO |
[thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA enilconazole results in increased expression of ALDH1A1 mRNA enilconazole results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ALDH2 |
aldehyde dehydrogenase 2 family member |
decreases expression multiple interactions |
EXP |
enilconazole results in decreased expression of ALDH2 mRNA [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein |
CTD |
PMID:32201337 PMID:34830855 |
|
NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532
|
|
G |
ANO1 |
anoctamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ANO1 mRNA |
CTD |
PMID:29106682 |
|
NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530
|
|
G |
ANXA10 |
annexin A10 |
increases expression |
EXP |
enilconazole results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 4:168,092,537...168,187,736
Ensembl chr 4:168,092,537...168,187,736
|
|
G |
AR |
androgen receptor |
multiple interactions decreases expression affects binding |
EXP ISO |
Dihydrotestosterone inhibits the reaction [enilconazole results in increased activity of AR protein]; enilconazole inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; enilconazole inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; enilconazole inhibits the reaction [Metribolone results in increased activity of AR protein] enilconazole results in decreased expression of AR mRNA enilconazole binds to AR protein |
CTD |
PMID:15064155 PMID:18324785 PMID:21310686 PMID:30853599 PMID:33049310 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ARG1 |
arginase 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332
|
|
G |
ATP8B1 |
ATPase phospholipid transporting 8B1 |
increases expression |
EXP |
enilconazole results in increased expression of ATP8B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
|
|
G |
CAT |
catalase |
increases expression |
ISO |
enilconazole results in increased expression of CAT mRNA |
CTD |
PMID:29451352 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
enilconazole results in increased expression of CCL5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CES2 |
carboxylesterase 2 |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein enilconazole results in decreased expression of CES2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CFTR |
CF transmembrane conductance regulator |
affects binding decreases expression |
ISO |
enilconazole binds to CFTR protein enilconazole results in decreased expression of CFTR mRNA; enilconazole results in decreased expression of CFTR protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
|
|
G |
COMT |
catechol-O-methyltransferase |
increases expression |
EXP |
enilconazole results in increased expression of COMT protein |
CTD |
PMID:32201337 |
|
NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,371...19,969,975
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
affects expression |
ISO |
enilconazole affects the expression of CYP11A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP17A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
decreases activity affects secretion |
EXP ISO |
enilconazole results in decreased activity of CYP19A1 protein enilconazole affects the secretion of CYP19A1 mRNA |
CTD |
PMID:10806373 PMID:15554355 PMID:26141389 PMID:30853599 |
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases activity increases expression multiple interactions |
EXP |
enilconazole results in increased activity of CYP1A1 protein enilconazole results in increased expression of CYP1A1 mRNA; enilconazole results in increased expression of CYP1A1 protein enilconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:19070657 PMID:21762035 PMID:32194361 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions affects expression |
EXP |
[clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA enilconazole affects the expression of CYP1A2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases expression multiple interactions |
EXP |
enilconazole results in increased expression of CYP1B1 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1B1 protein |
CTD |
PMID:32201337 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP27A1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
multiple interactions decreases expression |
EXP |
[clothianidin co-treated with enilconazole] results in decreased expression of CYP2A6 protein; [enilconazole co-treated with thiacloprid] results in decreased expression of CYP2A6 protein enilconazole results in decreased expression of CYP2A6 mRNA; enilconazole results in decreased expression of CYP2A6 protein |
CTD |
PMID:32201337 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases expression affects expression multiple interactions |
ISO EXP |
enilconazole results in increased expression of CYP2B10 enilconazole affects the expression of CYP2B6 mRNA [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA |
CTD |
PMID:27853109 PMID:32201337 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases expression |
EXP |
enilconazole results in decreased expression of CYP2C19 mRNA; enilconazole results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases expression |
EXP |
enilconazole results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions decreases expression |
EXP |
[clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA enilconazole results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions increases expression affects expression decreases activity |
EXP |
[Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [enilconazole co-treated with methidathion] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA enilconazole results in increased expression of CYP3A4 protein enilconazole affects the expression of CYP3A4 mRNA enilconazole results in decreased activity of CYP3A4 protein |
CTD |
PMID:21762035 PMID:25028461 PMID:32201337 PMID:34273450 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases expression multiple interactions |
EXP |
enilconazole results in increased expression of CYP3A5 mRNA; enilconazole results in increased expression of CYP3A5 protein [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein |
CTD |
PMID:32201337 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP3A7 |
cytochrome P450 family 3 subfamily A member 7 |
decreases expression |
EXP |
enilconazole results in decreased expression of CYP3A7 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196
|
|
G |
CYP51A1 |
cytochrome P450 family 51 subfamily A member 1 |
decreases activity |
EXP |
enilconazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of CYP7A1 mRNA [enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA enilconazole results in decreased expression of CYP7A1 mRNA; enilconazole results in decreased expression of CYP7A1 protein |
CTD |
PMID:29451352 PMID:32194361 PMID:32201337 PMID:32814239 PMID:33426623 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
CYP7B1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP8B1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DEFA3 |
defensin alpha 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of DEFA3 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 8:7,015,869...7,018,297
Ensembl chr 8:7,015,869...7,018,297
|
|
G |
DNM1 |
dynamin 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of DNM1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 9:128,203,379...128,255,244
Ensembl chr 9:128,191,655...128,255,248
|
|
G |
ELN |
elastin |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ELN mRNA [enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 7:74,028,173...74,069,907
Ensembl chr 7:74,027,789...74,069,907
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
EXP |
enilconazole binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
decreases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of ESR2 mRNA enilconazole binds to and results in increased activity of ESR2 protein |
CTD |
PMID:30853599 PMID:33049310 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
FABP6 |
fatty acid binding protein 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of FABP6 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735
|
|
G |
FAS |
Fas cell surface death receptor |
increases expression |
EXP |
enilconazole results in increased expression of FAS mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FGF19 |
fibroblast growth factor 19 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of FGF15 mRNA enilconazole results in increased expression of FGF15 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
GPX1 |
glutathione peroxidase 1 |
increases expression |
ISO |
enilconazole results in increased expression of GPX1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GPX2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of GPX2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GSR |
glutathione-disulfide reductase |
increases expression |
ISO |
enilconazole results in increased expression of GSR mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSS |
glutathione synthetase |
decreases expression |
ISO |
enilconazole results in decreased expression of GSS mRNA |
CTD |
PMID:29451352 |
|
NCBI chr20:34,928,432...34,956,027
Ensembl chr20:34,928,432...34,956,027
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions |
EXP |
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein |
CTD |
PMID:34830855 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HAAO |
3-hydroxyanthranilate 3,4-dioxygenase |
decreases expression |
EXP |
enilconazole results in decreased expression of HAAO mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:42,767,089...42,792,583
Ensembl chr 2:42,767,089...42,792,593
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression |
ISO |
enilconazole affects the expression of HMGCR mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
affects expression |
ISO |
enilconazole affects the expression of HMGCS1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HSD17B13 |
hydroxysteroid 17-beta dehydrogenase 13 |
decreases expression |
ISO |
enilconazole results in decreased expression of HSD17B13 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 4:87,303,794...87,322,882
Ensembl chr 4:87,303,789...87,322,886
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
enilconazole affects the expression of HSD3B1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
IFNG |
interferon gamma |
increases expression |
ISO |
enilconazole results in increased expression of IFNG mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL17A |
interleukin 17A |
multiple interactions increases expression |
ISO |
enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] enilconazole results in increased expression of IL17A mRNA |
CTD |
PMID:22289359 PMID:32814239 |
|
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
G |
IL1A |
interleukin 1 alpha |
increases expression |
ISO |
enilconazole results in increased expression of IL1A mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
increases expression |
ISO |
enilconazole results in increased expression of IL1B mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL22 |
interleukin 22 |
increases expression |
ISO |
enilconazole results in increased expression of IL22 mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr12:68,248,242...68,253,604
Ensembl chr12:68,248,242...68,253,604
|
|
G |
IL6 |
interleukin 6 |
increases expression |
ISO EXP |
enilconazole results in increased expression of IL6 mRNA |
CTD |
PMID:27393971 PMID:32201337 PMID:32814239 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
enilconazole results in increased expression of JUN mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KHK |
ketohexokinase |
decreases expression |
EXP |
enilconazole results in decreased expression of KHK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:27,086,772...27,100,762
Ensembl chr 2:27,086,772...27,100,762
|
|
G |
KLF4 |
KLF transcription factor 4 |
affects expression decreases expression |
ISO |
enilconazole affects the expression of KLF4 mRNA enilconazole results in decreased expression of KLF4 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
|
|
G |
KY |
kyphoscoliosis peptidase |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of KY mRNA [enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 3:134,599,923...134,651,022
Ensembl chr 3:134,599,923...134,651,636
|
|
G |
LCN2 |
lipocalin 2 |
increases expression |
ISO |
enilconazole results in increased expression of LCN2 |
CTD |
PMID:27393971 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LHB |
luteinizing hormone subunit beta |
decreases expression |
ISO |
enilconazole results in decreased expression of LHB protein |
CTD |
PMID:36410587 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LPL |
lipoprotein lipase |
increases expression |
EXP |
enilconazole results in increased expression of LPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LY6D |
lymphocyte antigen 6 family member D |
decreases expression |
EXP |
enilconazole results in decreased expression of LY6D mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:142,784,882...142,786,539
Ensembl chr 8:142,784,882...142,786,539
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases expression |
EXP |
enilconazole results in increased expression of MAPK8 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MEGF11 |
multiple EGF like domains 11 |
multiple interactions decreases expression |
ISO |
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA enilconazole results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr15:65,895,299...66,253,750
Ensembl chr15:65,895,079...66,253,756
|
|
G |
MEP1B |
meprin A subunit beta |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MEP1B mRNA enilconazole results in decreased expression of MEP1B mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:32,190,039...32,220,404
Ensembl chr18:32,185,069...32,220,404
|
|
G |
MLXIPL |
MLX interacting protein like |
decreases expression |
EXP |
enilconazole results in decreased expression of MLXIPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:73,593,202...73,647,907
Ensembl chr 7:73,593,194...73,624,543
|
|
G |
MME |
membrane metalloendopeptidase |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of MME mRNA [enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 3:155,024,202...155,183,729
Ensembl chr 3:155,024,124...155,183,704
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
decreases expression |
EXP |
enilconazole results in decreased expression of MTTP mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
MUC1 |
mucin 1, cell surface associated |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC1 mRNA enilconazole results in decreased expression of MUC1 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:155,185,824...155,192,915
Ensembl chr 1:155,185,824...155,192,916
|
|
G |
MUC17 |
mucin 17, cell surface associated |
decreases expression |
ISO |
enilconazole results in decreased expression of MUC17 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 7:101,020,081...101,058,859
Ensembl chr 7:101,020,072...101,058,859
|
|
G |
MUC2 |
mucin 2, oligomeric mucus/gel-forming |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC2 mRNA enilconazole results in decreased expression of MUC2 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr11:1,074,874...1,110,508
Ensembl chr11:1,074,875...1,110,511
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
multiple interactions decreases expression |
EXP |
[clothianidin co-treated with enilconazole] results in decreased expression of NR0B2 mRNA enilconazole results in decreased expression of NR0B2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of NR1H4 mRNA enilconazole results in increased expression of NR1H4 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions increases activity |
EXP ISO |
[enilconazole co-treated with methidathion] results in increased activity of NR1I2 protein; enilconazole binds to and results in increased activity of NR1I2 protein; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] enilconazole results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 PMID:17438109 PMID:21115097 PMID:25028461 PMID:29973476 PMID:33049310 More...
|
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions affects response to substance |
ISO |
enilconazole binds to and results in increased activity of NR1I3 protein; enilconazole inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein] NR1I3 protein affects the susceptibility to enilconazole |
CTD |
PMID:18832183 PMID:27853109 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
EXP |
enilconazole results in decreased expression of PDK4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PNPLA3 |
patatin like phospholipase domain containing 3 |
decreases expression |
EXP |
enilconazole results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr22:43,923,805...43,947,582
Ensembl chr22:43,923,792...43,964,488
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP ISO |
enilconazole binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
decreases expression |
EXP |
enilconazole results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RARA |
retinoic acid receptor alpha |
increases activity |
EXP |
enilconazole results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
|
|
G |
RARG |
retinoic acid receptor gamma |
increases activity |
EXP |
enilconazole results in increased activity of RARG protein |
CTD |
PMID:20143881 |
|
NCBI chr12:53,210,569...53,232,209
Ensembl chr12:53,210,567...53,232,980
|
|
G |
RETNLB |
resistin like beta |
affects expression |
ISO |
enilconazole affects the expression of RETNLB mRNA |
CTD |
PMID:29106682 |
|
NCBI chr 3:108,755,638...108,757,410
Ensembl chr 3:108,743,424...108,757,410
|
|
G |
RGCC |
regulator of cell cycle |
increases expression |
EXP |
enilconazole results in increased expression of RGCC mRNA |
CTD |
PMID:32201337 |
|
NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871
|
|
G |
RORA |
RAR related orphan receptor A |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of RORA protein |
CTD |
PMID:22289359 |
|
NCBI chr15:60,488,284...61,229,302
Ensembl chr15:60,488,284...61,229,302
|
|
G |
S100P |
S100 calcium binding protein P |
increases expression |
EXP |
enilconazole results in increased expression of S100P mRNA; enilconazole results in increased expression of S100P protein |
CTD |
PMID:32194361 |
|
NCBI chr 4:6,693,878...6,697,170
Ensembl chr 4:6,693,878...6,697,170
|
|
G |
SCD |
stearoyl-CoA desaturase |
decreases expression |
EXP |
enilconazole results in decreased expression of SCD mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC10A2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
enilconazole results in increased expression of SLC10A2 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
|
|
G |
SLC12A2 |
solute carrier family 12 member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC12A2 mRNA; enilconazole results in decreased expression of SLC12A2 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 5:128,083,766...128,189,677
Ensembl chr 5:128,083,766...128,189,677
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
decreases expression |
ISO EXP |
enilconazole results in decreased expression of SLC22A5 mRNA; enilconazole results in decreased expression of SLC22A5 protein |
CTD |
PMID:36150497 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC26A3 |
solute carrier family 26 member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A3 mRNA; enilconazole results in decreased expression of SLC26A3 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 7:107,765,469...107,803,223
Ensembl chr 7:107,765,467...107,803,225
|
|
G |
SLC26A6 |
solute carrier family 26 member 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A6 mRNA; enilconazole results in decreased expression of SLC26A6 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 3:48,625,723...48,635,461
Ensembl chr 3:48,625,723...48,635,493
|
|
G |
SLC6A1 |
solute carrier family 6 member 1 |
multiple interactions |
ISO |
[enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 3:10,992,748...11,039,247
Ensembl chr 3:10,992,186...11,039,247
|
|
G |
SLC9A3 |
solute carrier family 9 member A3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC9A3 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 5:470,456...524,449
Ensembl chr 5:470,456...524,449
|
|
G |
SLCO4A1 |
solute carrier organic anion transporter family member 4A1 |
increases expression |
EXP |
enilconazole results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr20:62,642,503...62,690,740
Ensembl chr20:62,642,503...62,685,785
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
ISO |
enilconazole results in increased expression of SOD1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SOD2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
STAR |
steroidogenic acute regulatory protein |
affects expression decreases expression |
ISO |
enilconazole affects the expression of STAR mRNA enilconazole results in decreased expression of STAR mRNA |
CTD |
PMID:30853599 PMID:36410587 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
SULT1B1 |
sulfotransferase family 1B member 1 |
decreases expression |
EXP |
enilconazole results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:69,721,167...69,760,620
Ensembl chr 4:69,721,167...69,787,961
|
|
G |
SULT1C2 |
sulfotransferase family 1C member 2 |
increases expression |
EXP |
enilconazole results in increased expression of SULT1C2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:108,288,895...108,309,915
Ensembl chr 2:108,288,639...108,309,915
|
|
G |
TFF3 |
trefoil factor 3 |
decreases expression |
EXP |
enilconazole results in decreased expression of TFF3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr21:42,311,667...42,315,409
Ensembl chr21:42,311,667...42,315,409
|
|
G |
THRA |
thyroid hormone receptor alpha |
multiple interactions |
EXP |
enilconazole binds to and results in decreased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
ISO |
enilconazole results in increased expression of TNF mRNA |
CTD |
PMID:27393971 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
UGT2B7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
EXP |
enilconazole results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:69,051,375...69,112,987
Ensembl chr 4:69,051,363...69,112,987
|
|